However, its value in the assessment of response to NAT in pancreatic cancer is still undetermined, as studies have reported inconclusive and diverse results, both regarding the classification of patients as responders and non-responders and the correlation with histopathological response [12–16]. This evidence concerns the gene BRD2 and pancreatic neoplasm.